Over the last decade, there has been a significant increase in the prevalence of cancer. According to the World Health Organization (WHO), cancer is the second leading cause of death globally. Nearly 1 in every 6 death occurs due to cancer. In 2015, cancer was responsible for 8.8 million deaths. Cervical cancer is the fourth most common cancer in females. The uncontrolled growth of cells in the cervical region of a uterus is called cervical cancer. Strains of Human Papillomavirus (HPV), generally a sexually transmitted antigen, are the general cause of cervical cancer. The disease begins when healthy cells acquire mutation leading to the uncontrolled growth of cells. These cells form a tumor which invades the nearby tissues. Cervical cancer is common in low and middle-income countries.
The major driver of cervical cancer treatment market is increasing in the prevalence of cervical cancer and growing awareness of the treatment of cervical cancer in women. As per WHO, cervical cancer accounts for 3.7% of all the cancers. In 2012, 528,000 women were diagnosed with cervical cancer. Unprotected sexual contact and multiple pregnancies increase the chance of cervical cancer. Moreover, the growing trend of consumption of alcohol and tobacco products at a young age is adding to the patient pool of cervical cancer.
However, the expensive devices used in the treatment of cancer & high expertise required adds to the high cost of treatment. Furthermore, side effects associated with the medicines & therapies used in treatment are the challenges for the growth of the market.
The limited number of treatment and medicines available creates an opportunity for key players of the market to introduce more cost-effective methods to cure cancer. Government and private players are investing a huge amount in research and development to improve cancer treatment methods which are expected to fuel the market in near future.
Globally, the cervical cancer treatment market is segmented into four regions; North America, Europe, Asia Pacific and Latin America, Middle East & Africa (LAMEA).
North America is expected to hold the major share in the market during the forecast period, owing to their huge patient pool. According to the National Cancer Institute, in 2015, there were an estimated 257,524 women living with cervical cancer in the United States. The region also has advanced technology for the treatment of cancer. Moreover, the prevalence of alcohol consumption and smoking are high in the region. According to data from Centers for Disease Control and Prevention (CDC), more than 15 in every 100 U.S adults smoke cigarettes.
European region holds a notable share of cervical cancer treatment market. This is attributed to their advancement in technology and growing cases of cervical cancer in the region. Unprotected sexual contact is prevalent in the region. Additionally, the favorable reimbursement policy and presence of key players in the region are driving the market growth.
During the forecast period, Asia Pacific region is predicted to show the fastest growth in cervical cancer treatment market. The growing geriatric population and increasing prevalence of cervical cancer in the region are the major drivers of the market. According to the WHO, among total cancer mortality in India, 20.7% is of cervix and uterus. The medical facilities of the region are not technically advanced, this creates the opportunity for market players to introduce advanced equipment in the region.
LAMEA region is expected to show slow growth in the market during the forecast period owing to their underdeveloped economies and lack of medical facilities. Among LAMEA, Middle East region should have the fastest growth as the healthcare facilities are improving in the region. However the area has huge potential, the patient pool is huge in LAMEA region. As per the WHO data, the cancer mortality of females in South Africa is 20,600 out of this 16.9% is attributed to cervix and uteri.
Novartis AG, Genentech USA, AstraZeneca plc, Eli Lilly and Company, Pfizer Inc., Allergan, Bristol-Myers Squibb Company, Actavis Pharma Company, Seimens Healthcare, QIAGEN and GlaxoSmithKline plc. are the key players working in global cervical cancer therapeutics.
Recently, Siemens Healthineers Company expanded its comprehensive sexually transmitted infections portfolio by adding an array of human papillomavirus (HPV) tests.
In 2011, Epigenomics AG the cancer molecular diagnostics company, and QIAGEN announced that the companies have entered into an option agreement allowing QIAGEN to develop and, should QIAGEN exercise the option, commercialize a colorectal cancer blood test.
Global Market Segmentation:
- Squamous Cell Carcinomas
- Adenosquamous Carcinomas
- Radiation Therapy
- Targeted Therapy
By End User
- Cancer care centers
- Research institutes
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Saudi Africa
- South Africa
- Rest of LAMEA